Financial Position - Cash position as of June 30, 2025, was $18.0 million, expected to fund operations into mid-2026[7] - Total assets as of June 30, 2025, were $19.1 million, a decrease from $19.8 million at the end of 2024[16] Expenses - Research and development expenses for Q2 2025 were $4.1 million, a slight decrease from $4.2 million in Q2 2024[7] - General and administrative expenses increased to $2.6 million in Q2 2025 from $2.4 million in Q2 2024[9] - Total operating expenses for Q2 2025 were $6.6 million, compared to $6.5 million in Q2 2024[18] Net Loss - Net loss for Q2 2025 was $6.0 million, or $0.40 per share, compared to a net loss of $4.0 million, or $0.36 per share, in Q2 2024[10] - Other income for Q2 2025 was $0.7 million, down from $2.6 million in Q2 2024, primarily due to decreased fair value adjustments[10] Clinical Trials and Development - Enrollment ongoing in Phase 2 KOURAGE trial with a target of 150 patients, data expected in early 2026[4] - Initial meeting with the FDA regarding Auxora for acute pancreatitis was productive, with alignment on a pivotal trial anticipated by the end of 2025[3] - Publication in the American Journal of Nephrology in June 2025 supports the development of Auxora for AKI treatment[4]
CalciMedica(CALC) - 2025 Q2 - Quarterly Results